Concordia International (NASDAQ:CXRX) (TSE:CXR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday.

According to Zacks, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada. “

How to Become a New Pot Stock Millionaire

Separately, ValuEngine upgraded shares of Concordia International from a “hold” rating to a “buy” rating in a research note on Friday, December 1st.

Concordia International (NASDAQ CXRX) opened at $0.61 on Friday. The firm has a market cap of $31.28, a PE ratio of -0.02 and a beta of 1.09. Concordia International has a 52 week low of $0.45 and a 52 week high of $2.27. The company has a debt-to-equity ratio of -2.38, a quick ratio of 1.46 and a current ratio of 1.68.

A hedge fund recently raised its stake in Concordia International stock. Renaissance Technologies LLC lifted its position in shares of Concordia International Corp (NASDAQ:CXRX) (TSE:CXR) by 196.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 455,983 shares of the company’s stock after purchasing an additional 302,284 shares during the period. Renaissance Technologies LLC owned 0.89% of Concordia International worth $300,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/03/11/concordia-international-cxrx-stock-rating-upgraded-by-zacks-investment-research.html.

About Concordia International

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Get a free copy of the Zacks research report on Concordia International (CXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with MarketBeat.com's FREE daily email newsletter.